All In Biotech

Drug Trial Radar · NCT07229586

A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors

A Phase IB/II Clinical Study of the Safety, Tolerability and Efficacy of SHR-7367 in Combination With Anti-tumor Agents in Subjects With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Dec 2, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety and preliminary efficacy of SHR-7367 in combination with antineoplastic agents in subjects with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).

Conditions

  • Solid Tumor

Interventions

  • SHR-7367 InjectionDrug

    SHR-7367 injection.

  • SHR-1316 InjectionDrug

    SHR-1316 injection.

  • Paclitaxel for InjectionDrug

    Paclitaxel for injection (Albumin Bound).

  • Gemcitabine Hydrochloride for InjectionDrug

    Gemcitabine Hydrochloride for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1 (IB Period): Dose-limiting toxicity (DLT).Time frame: Up to 28 days.
  2. Stage 1 (IB Period): Adverse events (AEs).Time frame: About 1 year.
  3. Stage 1 (IB Period): Serious adverse events (SAEs).Time frame: About 1 year.
  4. Phase II: Investigator-assessed objective response rate (ORR).Time frame: Assessed every 6 weeks, about 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.